IP Verse

Rapamycin Derivative For Treating Advanced Solid Tumours - EP3345602

The patent EP3345602 was granted to Novartis on Apr 6, 2022. The application was originally filed on Feb 18, 2002 under application number EP18155722A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3345602

NOVARTIS
Application Number
EP18155722A
Filing Date
Feb 18, 2002
Status
Granted And Under Opposition
Mar 4, 2022
Publication Date
Apr 6, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHYPHARMJan 6, 2023LLRWITHDRAWN
GENERICS UKJan 6, 2023ELKINGTON AND FIFEWITHDRAWN
STADA ARZNEIMITTELJan 4, 2023HAMM & WITTKOPPWITHDRAWN

Patent Citations (57) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0296110
DESCRIPTIONEP0520722
DESCRIPTIONEP0564409
DESCRIPTIONEP0566226
DESCRIPTIONEP0769947
DESCRIPTIONEP0787722
DESCRIPTIONEP0837063
DESCRIPTIONGB2177700
DESCRIPTIONUS4100274
DESCRIPTIONUS4636505
DESCRIPTIONUS4659516
DESCRIPTIONUS5010099
DESCRIPTIONUS5362718
DESCRIPTIONUS5747498
DESCRIPTIONUS5843901
DESCRIPTIONWO0009495
DESCRIPTIONWO0027819
DESCRIPTIONWO0027820
DESCRIPTIONWO0037502
DESCRIPTIONWO0059509
DESCRIPTIONWO9409010
DESCRIPTIONWO9410202
DESCRIPTIONWO9503283
DESCRIPTIONWO9516691
DESCRIPTIONWO9630347
DESCRIPTIONWO9633980
DESCRIPTIONWO9641807
DESCRIPTIONWO9702266
DESCRIPTIONWO9730034
DESCRIPTIONWO9738983
DESCRIPTIONWO9749688
DESCRIPTIONWO9810767
DESCRIPTIONWO9811223
DESCRIPTIONWO9835958
DESCRIPTIONWO9903854
DESCRIPTIONWO9917804
OPPOSITIONEP2269603
OPPOSITIONEP2269604
OPPOSITIONEP2275103
OPPOSITIONEP2762140
OPPOSITIONEP2783686
OPPOSITIONEP3143995
OPPOSITIONEP3342411
OPPOSITIONEP3345602
OPPOSITIONEP3351246
OPPOSITIONUS5206018
OPPOSITIONUS6183721
OPPOSITIONWO0112633
OPPOSITIONWO0151049
OPPOSITIONWO02066019
OPPOSITIONWO9409010
OPPOSITIONWO9409019
OPPOSITIONWO9747317
OTHERWO9747317
SEARCHWO0151049
SEARCHWO9409010
SEARCHWO9747317

Non-Patent Literature (NPL) Citations (45) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- CLARK, Breast Cancer Research Treatment, (19970000), vol. 46, page 255
DESCRIPTION- F. YUAN et al., Proc. Natl. Acad. Sci. USA, (19961200), vol. 93, pages 14765 - 14770
DESCRIPTION- J. MORDENTI et al., Toxicologic Pathology, (19990000), vol. 27, no. 1, pages 14 - 21
DESCRIPTION- M. PREWETT et al., Cancer Research, (19990000), vol. 59, pages 5209 - 5218
DESCRIPTION- M. S. O'REILLY et al., Cell, (19940000), vol. 79, pages 315 - 328
DESCRIPTION- M. S. O'REILLY et al., Cell, (19970000), vol. 88, pages 277 - 285
DESCRIPTION- Z. ZHU et al., Cancer Res., (19980000), vol. 58, pages 3209 - 3214
EXAMINATION- Anonymous, "Cancer Classification | SEER Training", (20210304), URL: https://training.seer.cancer.gov/disease/categories/classification.html, (20210304), XP055782207
EXAMINATION- Chapter 109, "Pathology of malignant- lymphomas", Chapter 109, Peter M. Banks, Williams Hematology, US, McGraw-Hill, (1995), pages 1045 - 1057, ISBN 0-07-070386-8, XP009526015
EXAMINATION- Cohen Mervyn D ET AL, "Visual Presentation of the Staging of Pediatric Solid Tumors1", RadloGraphicsC.. EMil.. M, (19960101), pages 523 - 545, URL: https://pubs.rsna.org/doi/pdf/10.1148/radiographics.16.3.8897621, (20210301), XP055780842
EXAMINATION- Dumont, "Everolimus Novartis", CURR OPIN INVESTIG DRUGS, (20010101), pages 1220 - 1234, XP055639440
EXAMINATION- Iwan Beuvink ET AL, "1972 Antitumor Activity of RAD001, an Orally Active Repamycin Derivative", Proceedings of the American Association for Cancer research, (20010301), vol. 42, page 366, XP055621157
EXAMINATION- ROWLEY ET AL, "Chromosome abnormalities in cancer", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 2, no. 2, doi:10.1016/0165-4608(80)90059-X, ISSN 0165-4608, (19800901), pages 175 - 198, (19800901), XP023451082
EXAMINATION- Harris Nl ET AL, "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]", Blood, US, (19940901), vol. 84, no. 5, doi:10.1182/blood.V84.5.1361.1361, ISSN 0006-4971, pages 1361 - 1392, XP055781915
OPPOSITION- ALEXANDRE; JEROME; RAYMOND; ERIC; ARMAND; JEAN-PIERRE, "La rapamycine et le CCI-779", Bull Cancer, (19990000), vol. 86, pages 808 - 811, XP002201077
OPPOSITION- BEUVINK et al., "1972 Antitumor Activity of RAD001, an Orally Active Repamycin Derivative", Proceedings of the American Association for Cancer research, (20010000), vol. 42, page 366, XP055621157
OPPOSITION- BEUVINK, I. et al., "Antiumour activity of RAD001, an orally active rapamycin derivative", 92nd Annual Meeting of American Association for Cancer Research, (20010300), vol. 42, page 366, XP093016793
OPPOSITION- DUMONT, F. J., "Everolimus, Novartis", Current Opinion in Investigational Drugs, (20010000), vol. 2, no. 9, pages 1220 - 1234, XP055639440
OPPOSITION- ENG C P et al., "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", THE JOURNAL OF ANTIBIOTICS, GB, (19841000), vol. 37, no. 10, ISSN 0021-8820, pages 1231 - 1237, XP001095310
OPPOSITION- GEORGER, B. et al., "Antitumour Activity of the Rapamycin Analog CCI-779 in Human Primitive Neuroectodermal Tumour/Medulloblastoma Models as Single Agent and in Combination Chemotherapy", Cancer Research, (20010215), vol. 61, pages 1527 - 1532, XP002201076
OPPOSITION- GIBBONS et al., "Pharmacology and experimental therapeutics 17", Proceedings of the American association, (19990000), vol. 40, page 301, XP093016891
OPPOSITION- Grewe Martin, Gansauge Frank, Schmid Roland M, Adler Guido, Seufferlein Thomas, "Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active FRAP-p70 s6K Pathway in Human Pancreatic Cancer Cells 1", Cancer Research, (19990000), vol. 59, pages 3581 - 3587, XP055701509
OPPOSITION- GUBA et al., "Rapamycin inhibits tumor growth and metastasis by angiogenesis", Chirurgisches forum 2001 für experimentelle und klinische Forschung, (20010000), pages 38 - 39, XP093016872
OPPOSITION- Hoffman, "Orthotopic metastatic mouse for anticancer drug discovery and evolution:a bridge to the clinic", Investigational New Drugs, (19990101), vol. 17, pages 343 - 359, XP055639400
OPPOSITION- HOSOI et al., "Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells", Cancer Res., (19990215), vol. 59, no. 4, pages 886 - 894, XP001154916
OPPOSITION- IACOVELLI, R. et al., "Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma", Clinical Genitourinary Cancer, (20150000), vol. 13, no. 2, pages 137 - 141, XP093016790
OPPOSITION- PATEL, S. et al., "Everolimus versus temsirolimus in metastatic renal cell carcinoma after progression with previous systemic therapies", Clinical Genitourinary Cancer, (20160000), vol. 14, no. 2, pages 153 - 159, XP093016791
OPPOSITION- RAYMOND et al., "CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: A phase I study utilizing a weekly intravenous schedule", Clin. Cancer. Res., (20000000), vol. 6, page 414S, XP055422919
OPPOSITION- RAYMOND et al., "CCI-779, a Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule", THIRTY-SIXTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, New Orleans, LA, (20000501), page 187a, XP055422938
OPPOSITION- SHAH et al., "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", Journal of Surgical Research, (20010000), vol. 97, no. 2, pages 123 - 130, XP029590080
OPPOSITION- SEDRANI, R. et al., "Chemical modification of Rapamycin: The Discovery of SDZ RAD", Transplantation proceedings, (19980000), vol. 30, doi:10.1016/S0041-1345(98)00587-9, pages 2192 - 2194, XP000925138
OPPOSITION- SEDRANI R., ET AL., "CHEMICAL MODIFICATION OF RAPAMYCIN: THE DISCOVERY OF SDZ RAD.", TRANSPLANTATION PROCEEDINGS, Elsevier Inc., ORLANDO, FL; US, ORLANDO, FL; US , (19980801), vol. 30., no. 05., doi:10.1016/S0041-1345(98)00587-9, ISSN 0041-1345, pages 2192 - 2194., XP000925138
OPPOSITION- SHU Z, "Recent natural products based drug development: a pharmaceutical industry perspective", J. Nat. Prod., (19980000), vol. 61, pages 1053 - 1071, XP001120005
OPPOSITION- Hidalgo Manuel; Rowinsky Eric K, "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogen, (20000000), vol. 19, pages 6680 - 6696, XP037733311
OPPOSITION- HIDALGO, M. et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), vol. 19, doi:10.1038/sj.onc.1204091, pages 6680 - 6686, XP037733311
OPPOSITION- HIDALGO M, ROWINSKY E K, "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, Nature Publishing Group UK, London, London , (20001227), vol. 19, no. 56, doi:10.1038/sj.onc.1204091, ISSN 0950-9232, pages 6680 - 6686, XP002323912
OPPOSITION- HUANG S; HOUGHTON P J, "Mechanisms of resistance to rapamycins", Drug Resistance Updates, (20010000), vol. 4, pages 378 - 391, XP001094520
OPPOSITION- MAJEWSKI M et al., "THE IMMUNOSUPPRESSIVE MACROLIDE PAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20000411), vol. 97, no. 8, ISSN 0027-8424, pages 4285 - 4290, XP001093844
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
OPPOSITION- SCHULER, W. et al., "SDZ RAD, a new rapamycin derivative", Transplantation, vol. 64, no. 1, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
OTHER- BEUVINK et al., "ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proc. Am. Ass. Cancer Research, (20010300), vol. 42, page 366, XP001093826
OTHER- DUMONT FJ, "Everolimus Novartis", Curr. Opin. Investig. Drugs, (20010900), vol. 2, no. 9, pages 1220 - 1234, XP055639440
SEARCH- ENG C P ET AL, "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", THE JOURNAL OF ANTIBIOTICS, NATURE PUBLISHING GROUP, GB, (198410), vol. 37, no. 10, ISSN 0021-8820, pages 1231 - 1237, XP001095310 [Y] 1-5 * table 3 * * abstract *
SEARCH- RAYMOND ET AL, "CCI-779, a Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule", THIRTY-SIXTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, New Orleans, LA, (200005), page 187a, XP055422938 [Y] 1-5 * abstract *
SEARCH- MAJEWSKI M ET AL, "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20000411), vol. 97, no. 8, doi:10.1073/PNAS.080068597, ISSN 0027-8424, pages 4285 - 4290, XP001093844 [I] 1-5 * abstract * * page 4289, column 2, paragraph 2 * [Y] 1-5

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents